Diffuse large B-cell lymphoma and other aggressive B-cell lymphomas
Research activity includes diffuse large B-cell lymphoma, relapsed/refractory aggressive B-NHL, primary diffuse large B-cell lymphoma of the CNS, and other high-risk B-cell malignancies, with interest in both newly diagnosed and relapsed settings.
- CAR T-cell therapy
- Bispecific antibodies
- Anti-CD19 and anti-CD20 approaches
- Lenalidomide-based combinations
Additional work spans molecular response, complete response, and progression-free survival in aggressive lymphoma subtypes.
Follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma
The sponsor funds studies in follicular lymphoma, including high-risk and untreated disease, as well as mantle cell lymphoma and marginal zone lymphoma, covering both frontline and relapsed/refractory care.
- EZH2-targeted therapy
- BCL2-directed combinations
- BTK inhibitor-based regimens
- CD20-directed immunotherapy
Key interests include response depth, minimal residual disease, and disease control in indolent and intermediate-grade lymphomas.
Peripheral T-cell lymphoma and related T-cell malignancies
LYSARC supports research in peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, PTCL-NOS, PTCL-TFH, anaplastic large cell lymphoma, and other rare T-cell neoplasms.
- Relapsed/refractory disease management
- Maintenance therapy
- Autologous stem cell transplantation
- Immune-based combinations
Studies also address modified progression-free survival and treatment sequencing in aggressive T-cell lymphoma subtypes.
Post-CAR T-cell strategies and refractory lymphoma
Another focus area is disease control after CAR T-cell therapy, particularly in relapsed/refractory lymphoma and high-risk B-cell lymphoma with persistent or recurrent disease.
- Glofitamab
- Golcadomide
- Epcoritamab
- Tafasitamab
Research also includes combinations built around lenalidomide, rituximab, and other immune-modulating therapies for patients with limited treatment options.
Rare lymphoma subtypes and advanced disease settings
The portfolio extends to primary central nervous system lymphoma, Hodgkin lymphoma, and uncommon entities such as lymphoplasmacytic lymphoma, adult T-cell leukemia/lymphoma, hepatosplenic T-cell lymphoma, and extranodal NK/T-cell lymphoma.
- Valemetostat
- Lacutamab
- Venetoclax
- Rituximab
These studies examine relapsed/refractory disease, high-risk lymphoma, and treatment approaches for rare histologies across multiple lymphoid cancers.
